Latest News | Glenmark Pharmaceuticals Launches Generic Version of Diuretic Bumetanide Injection

New Delhi, Jan 10 (PTI) Glenmark Pharmaceuticals Ltd on Tuesday said its US arm has launched its generic version of diuretic Bumetanide injection.

In a statement the company said Glenmark Pharmaceuticals Inc., USA (Glenmark) launched Bumetanide Injection of strengths of 1 mg/4 mL (0.25 mg/mL) single-dose vials and 2.5 mg/10 mL (0.25 mg/mL) multi-dose vials.

Also Read | Auto Expo – The Motor Show 2023 To Be Held From January 13 to 18 in Greater Noida, Will Explore Futuristic Green Tech.

These are the generic version of Bumex injection, 0.25 mg/mL, of Validus Pharmaceuticals LLC, it added.

The launch affirms commitment to Glenmark's continued focus on institutional business, company Senior Vice President, Business Development Portfolio, Product Launch & Strategy, Vijay Raghavan said.

Also Read | 7th Pay Commission: Latest AICPI Figure Released, Here's What It Means For DA Hike in 2023.

The Bumex injection, 0.25 mg/mL achieved annual sales of approximately USD 16.5 million, the company said citing IQVIA sales data for the 12-month period ended November 2022.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)